NF2 and neurocutaneous syndrome: Patients with neurocutaneous syndromes represented 29.6% of our cohort (42/142): 21 patients (14.8%) were affected by NF1, 15 patients (10.6%) by schwannomatosis, and 6 (4.2%) by NF2.